BlueCrest Capital Management Ltd Acquires Shares of 74,292 Senseonics Holdings Inc (SENS)

BlueCrest Capital Management Ltd bought a new stake in Senseonics Holdings Inc (NYSEAMERICAN:SENS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 74,292 shares of the company’s stock, valued at approximately $198,000. BlueCrest Capital Management Ltd owned about 0.05% of Senseonics at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Bank of New York Mellon Corp purchased a new position in shares of Senseonics during the 3rd quarter worth approximately $116,000. Perceptive Advisors LLC acquired a new position in shares of Senseonics in the 3rd quarter valued at $160,000. Citadel Advisors LLC acquired a new position in shares of Senseonics in the 3rd quarter valued at $194,000. Finally, Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Senseonics by 33.1% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 350,750 shares of the company’s stock valued at $1,119,000 after acquiring an additional 87,188 shares in the last quarter. 30.66% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

In other Senseonics news, COO Mukul Jain sold 24,294 shares of the firm’s stock in a transaction dated Friday, April 6th. The shares were sold at an average price of $3.75, for a total value of $91,102.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders sold 67,437 shares of company stock valued at $240,741. Corporate insiders own 34.10% of the company’s stock.

A number of brokerages have commented on SENS. Guggenheim began coverage on shares of Senseonics in a report on Tuesday, April 3rd. They issued a “buy” rating and a $6.00 price objective on the stock. Canaccord Genuity reaffirmed a “buy” rating on shares of Senseonics in a research report on Friday, March 2nd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $4.83.

Shares of SENS stock traded up $0.09 during trading hours on Thursday, reaching $3.74. 1,157,600 shares of the stock traded hands, compared to its average volume of 795,097. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.81 and a current ratio of 2.93. Senseonics Holdings Inc has a 1-year low of $1.26 and a 1-year high of $4.00.

Senseonics (NYSEAMERICAN:SENS) last announced its quarterly earnings results on Tuesday, March 13th. The company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.01. Senseonics had a negative net margin of 828.76% and a negative return on equity of 406.72%. The company had revenue of $2.90 million for the quarter, compared to analyst estimates of $2.95 million. The business’s revenue for the quarter was up 866.7% on a year-over-year basis. research analysts anticipate that Senseonics Holdings Inc will post -0.54 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “BlueCrest Capital Management Ltd Acquires Shares of 74,292 Senseonics Holdings Inc (SENS)” was first posted by Macon Daily and is owned by of Macon Daily. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://macondaily.com/2018/04/12/bluecrest-capital-management-ltd-purchases-new-stake-in-senseonics-holdings-inc-sens-updated-updated-updated.html.

Senseonics Company Profile

Senseonics Holdings, Inc is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes.

Institutional Ownership by Quarter for Senseonics (NYSEAMERICAN:SENS)

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply